NewEdge Advisors’s First Trust Nasdaq Pharmaceuticals ETF FTXH Stock Holding History

NewEdge Advisors’s Portfolio FTXH Stock Details FTXH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$18M	Buy	+434,003	New	+$17.5M	0.05%	342
2024 Q4	–	Sell	-21,350	Closed	-$616K	–	3951
2024 Q3	$616K	Buy	+21,350	New	+$611K	﹤0.01%	1353
2023 Q4	–	Sell	-7,274	Closed	-$186K	–	3792
2023 Q3	$186K	Buy	7,274 +532	+8%	+$14.1K	﹤0.01%	1654
2023 Q2	$177K	Sell	6,742 -907	-12%	-$24K	﹤0.01%	1678
2023 Q1	$200K	Buy	7,649 +1,384	+22%	+$37.1K	﹤0.01%	1545
2022 Q4	$172	Buy	+6,265	New	+$167K	﹤0.01%	3316

Other funds holding FTXH

First Trust Advisors Wheaton, Illinois $170B AUM 38.25% 1-Year Est. Return

Nilsine Partners Greenwood Village, Colorado $1.44B AUM 38.08% 1-Year Est. Return

LPL Financial San Diego, California $468B AUM 17.69% 1-Year Est. Return

NewSquare Capital Newtown Square, Pennsylvania $1.38B AUM 24% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $375B AUM 21.05% 1-Year Est. Return

Summit Financial Parsippany, New Jersey $9.42B AUM 19.31% 1-Year Est. Return

Benjamin Edwards Inc Clayton, Missouri $11.1B AUM 12.46% 1-Year Est. Return

Oppenheimer & Co New York $9.5B AUM 27.65% 1-Year Est. Return

Advisory Services Network Atlanta, Georgia $8.32B AUM 29.07% 1-Year Est. Return

Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return

NewEdge Advisors's FTXH Position: Q3 2026 in Review

NewEdge Advisors opened a new position in First Trust Nasdaq Pharmaceuticals ETF (FTXH) in Q3 2026: 434,003 shares worth $18M. The stake represents 0.05% of the portfolio and ranks #342 among its holdings. This is a return to the name: NewEdge Advisors previously reported a position in FTXH as recently as Q3 2024.

NewEdge Advisors first reported a position in FTXH in Q4 2022 and has held it in 6 quarters since. 57 funds tracked by Wall St. Rank hold FTXH as of Q3 2026.

NewEdge Advisors held 434,003 shares of First Trust Nasdaq Pharmaceuticals ETF worth $18M as of Q3 2026.
First Trust Nasdaq Pharmaceuticals ETF was a new NewEdge Advisors position in Q3 2026.
First Trust Nasdaq Pharmaceuticals ETF made up 0.05% of NewEdge Advisors's portfolio in Q3 2026, its #342 holding.
NewEdge Advisors first reported a position in First Trust Nasdaq Pharmaceuticals ETF in Q4 2022 and has held it in 6 quarters since.
57 funds tracked by Wall St. Rank held First Trust Nasdaq Pharmaceuticals ETF as of Q3 2026.

Based on NewEdge Advisors's 13F filing for Q3 2026, filed 13 Nov 2026.